LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial

Post time 6 day(s) ago

journal：Clinical Cancer Research

Authors：Jun Cai; Baitian Zhao; Dongmei Ji; Fuling Zhou; Shenrui Bai; Xiaojie Fang; Man Nie; Bing Bai; Yuchen Zhang; Jin Li; Haoyuan Li; Yuan Li; Da Fei; Xia Qin; Crystal Qin; Shuiyu Zhao; Yi Xia; Qingqing Cai

Published date：2026-6-15

DOI：10.1158/1078-0432.ccr-25-2357

PDF link：https://aacrjournals.org/clincan ... 577/ccr-25-2357.pdf

Article link：https://doi.org/10.1158/1078-0432.ccr-25-2357

Article Source：American Association for Cancer Research (AACR)。

Remark：

Post time 6 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AACR] LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AACR] LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial Copy